Ferroptosis in Cancer Therapy: Mechanisms, Small Molecule Inducers, and Novel Approaches
YiLin Luo,Xin Yue Bai,Lei Zhang,Qian Qian Hu,Ning Zhang,Jun Zhi Cheng,Ming Zheng Hou,Xiao Long Liu
DOI: https://doi.org/10.2147/dddt.s472178
IF: 4.3188
2024-06-22
Drug Design Development and Therapy
Abstract:YiLin Luo, Xin Yue Bai, Lei Zhang, Qian Qian Hu, Ning Zhang, Jun Zhi Cheng, Ming Zheng Hou, Xiao Long Liu Yan 'an Small Molecule Innovative Drug R&D Engineering Research Center, School of Medicine, Yan'an University, Yan'an, People's Republic of China Correspondence: Xiao Long Liu, Email Ferroptosis, a unique form of programmed cell death, is initiated by an excess of iron accumulation and lipid peroxidation-induced damage. There is a growing body of evidence indicating that ferroptosis plays a critical role in the advancement of tumors. The increased metabolic activity and higher iron levels in tumor cells make them particularly vulnerable to ferroptosis. As a result, the targeted induction of ferroptosis is becoming an increasingly promising approach for cancer treatment. This review offers an overview of the regulatory mechanisms of ferroptosis, delves into the mechanism of action of traditional small molecule ferroptosis inducers and their effects on various tumors. In addition, the latest progress in inducing ferroptosis using new means such as proteolysis-targeting chimeras (PROTACs), photodynamic therapy (PDT), sonodynamic therapy (SDT) and nanomaterials is summarized. Finally, this review discusses the challenges and opportunities in the development of ferroptosis-inducing agents, focusing on discovering new targets, improving selectivity, and reducing toxic and side effects. Keywords: ferroptosis inducers, small molecules, PROTACs, PDT, SDT, nanomaterials The latest data released by the International Agency for Research on Cancer (IARC) indicates that there were 20 million new cancer cases globally in 2022, resulting in 9.7 million deaths. This data highlights the increasing global burden of cancer. 1 However, the effectiveness of existing cancer treatments is concerning, as tumor cell resistance is reducing the efficacy of conventional therapies like radiotherapy and chemotherapy. 2 Additionally, refractory cancers like small cell lung cancer (SCLC), 3 triple-negative breast cancer (TNBC), 4 and pancreatic cancer 5 present significant challenges in oncology treatment due to their resistance to existing therapies. Ferroptosis, a novel iron-dependent form of programmed cell death first proposed by Dr. Brent R. Stockwell in 2012, is distinct from apoptosis, necrosis, and autophagy. 6 It is triggered by glutathione (GSH) depletion, decreased activity of glutathione peroxidase 4 (GPX4), failure of lipid oxides to be metabolized by GPX4, and Fe 2+ -mediated oxidation of lipids leading to the generation of reactive oxygen species (ROS) that promote ferroptosis. 7 Ferroptosis provides a new way of thinking about cancer treatment. Ferroptosis induction therapy has several natural advantages for cancer treatment. Firstly, the unique metabolism of cancer cells, the high load of ROS, and their specific mutations make some of them sensitive to ferroptosis, 8 eg, clear cell renal cell carcinoma (ccRCC), 9 pancreatic ductal adenocarcinoma, 10 and TNBC. 11 Cancer cells typically require more iron than normal cells to proliferate, and this iron dependence makes them more susceptible to ferroptosis. 12 Cancer cells with a high mesenchymal state were found to be more resistant to a wide range of cancer treatments but were particularly susceptible to ferroptosis inducers. 13 Also, ferroptosis induction therapy can be used in combination with conventional tumor treatments to enhance their therapeutic effects in certain malignancies. 14 Ferroptosis-inducing therapies have emerged as a crucial strategy in oncology, with ongoing advancements in the development and study of various small molecule drugs targeting ferroptosis-regulating pathways. 15 This review provides an overview of the regulatory mechanisms of ferroptosis and delves into the mechanisms of traditional small molecule ferroptosis inducers and their effects on various tumors. It also highlights the recent progress in inducing ferroptosis through innovative methods such as PROTACs, PDT, SDT, and nanomaterials. Furthermore, the review addresses the challenges and opportunities in developing ferroptosis-inducing agents, including the exploration of new targets, enhancement of selectivity, and mitigation of toxic and side effects (Figure 1). Figure 1 Ferroptosis in cancer therapy. Ferroptosis is a new form of cell death characterized by iron-dependent accumulation of lipid peroxidation to lethal levels. 16 It has been shown that in mammalian cells, ferroptosis is mainly regulated by iron homeostasis, lipid metabolism, and glutathione-dependent redox homeostasis (Figure 2). Figure 2 Ferroptosis mechanisms and their associated inducers of ferroptosis -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal